NCT01372137View on ClinicalTrials.gov

First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NOX-H94

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
AnemiaChronic DiseasesInflammation
Interventions
DRUG

NOX-H94

Dosage form: NOX-H94 25 mg (oligonucleotide basis) Solution for Injection Strength: 14.6 mg NOX-H94 / mL Dose: 0.3 - 4.8 mg/kg single dose Route: IV infusion over 15 minutes / SC administration

OTHER

Glucose 5%

Placebo

Trial Locations (1)

NW10 7EW

HMR, London

All Listed Sponsors
lead

TME Pharma AG

INDUSTRY

NCT01372137 - First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NOX-H94 | Biotech Hunter | Biotech Hunter